GENE ONLINE|News &
Opinion
Blog

FDA Approval
Takeda’s Livtencity Bags FDA Approval for the Treatment of Post-Transplant Infection
2021-11-24
FDA Approves Aadi Bioscience’s First Product to Treat Rare Cancer
2021-11-23
BioMarin’s Dwarfism Drug Garners FDA Nod Amidst Concerns Over Threat to Dwarf Pride
2021-11-21
Oyster Point’s Nasal Spray for Dry Eyes Notches FDA Approval
2021-10-19
FDA Greenlights First and Only Treatment for Cholestatic Pruritus with ALGS
2021-10-04
FDA Approves Kite’s CAR-T Therapy for Adult Leukemia
2021-10-04
FDA Approves Samsung Bioepis and Biogen’s Lucentis Biosimilar
2021-09-22
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06
Janssen’s Long-acting Schizophrenia Drug Notches FDA Approval
2021-09-02
Jazz Pharma’s Xywav Becomes First FDA Approved Drug for a Rare Neurologic Disease
2021-08-13
Albireo Gets Back-to-Back Approvals for Rare Liver Disease Drug
2021-07-26
FDA Okays Bayer’s Kidney Disease Drug, Kicking Off Market Rivalry Against Established SGLT-2 Inhibitors
2021-07-12
FDA Approves Jazz Pharma’s Rylaze for Treating Common Leukemia in Children
2021-07-04
FDA Greenlights Blueprint Medicines’ Ayvakit for Rare Disease Treatment
2021-06-21
Biogen’s Controversial Alzheimer’s Drug Wins Historic FDA Approval
2021-06-07
1 2 3 5
LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!